CRISPR Therapeutics (Germany) Performance
| 1CG Stock | 40.80 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and CRISPR Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 939.9 M | |
| Free Cash Flow | -532.9 M |
CRISPR |
CRISPR Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,080 in CRISPR Therapeutics AG on October 10, 2024 and sell it today you would earn a total of 0.00 from holding CRISPR Therapeutics AG or generate 0.0% return on investment over 90 days. CRISPR Therapeutics AG is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Simply put, 0% of stocks are less volatile than CRISPR, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
CRISPR Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CRISPR Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CRISPR Therapeutics AG, and traders can use it to determine the average amount a CRISPR Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| 1CG |
Based on monthly moving average CRISPR Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CRISPR Therapeutics by adding CRISPR Therapeutics to a well-diversified portfolio.
CRISPR Therapeutics Fundamentals Growth
CRISPR Stock prices reflect investors' perceptions of the future prospects and financial health of CRISPR Therapeutics, and CRISPR Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CRISPR Stock performance.
| Current Valuation | 2.16 B | |||
| Price To Book | 6.67 X | |||
| Price To Sales | 1,731 X | |||
| Revenue | 436 K | |||
| EBITDA | (648.99 M) | |||
| Cash Flow From Operations | (495.74 M) | |||
| Total Asset | 2.24 B | |||
About CRISPR Therapeutics Performance
Assessing CRISPR Therapeutics' fundamental ratios provides investors with valuable insights into CRISPR Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the CRISPR Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about CRISPR Therapeutics performance evaluation
Checking the ongoing alerts about CRISPR Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CRISPR Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CRISPR Therapeutics generated a negative expected return over the last 90 days | |
| CRISPR Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 436 K. Net Loss for the year was (650.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CRISPR Therapeutics generates negative cash flow from operations |
- Analyzing CRISPR Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CRISPR Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CRISPR Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CRISPR Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CRISPR Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CRISPR Therapeutics' stock. These opinions can provide insight into CRISPR Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.